A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

Trial Details

NCT ID
NCT04370587
Phase
PHASE1 / PHASE2
Sponsor
ImmVira Pharma Co. Ltd
Status
RECRUITING
Cancer Type
Melanoma
Locations (sample)
  • Gilbert, Arizona, United States|33.35283,-111.78903
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Age 18 years or older.
  • Disease progression after standard of care (SOC) therapy or in the opinion of
  • The Investigator unlikely to benefit from SOC therapy. Inclusion Diagnosis Phase 1 - Histologically or pathologically confirmed locally recurrent o…
  • Phase 2a Part 1 i. Arm A - locally recurrent or metastatic melanoma. Participants must have received no more than 3 prior regimens for advanced or …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →